Dr. Laszlo L. Mechtler, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 42
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 866
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
NY license 171164
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Kaleida Health Buffalo, NY
Medical groups
- Roswell PArk Cancer Institute (488 clinicians)
- Dent Neurologic Group LLP (116 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 866
- Services billed
- 20,300
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Injection, gadobenate dimeglumine (multihance multipack), per ml | 2,343 | 242 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2,150 | 26 |
| Mri scan of brain without contrast | 323 | 313 |
| Mri scan of brain before and after contrast | 193 | 172 |
| Established patient office or other outpatient visit, 30-39 minutes | 152 | 109 |
| 3d radiographic procedure with computerized image postprocessing | 107 | 107 |
| Ultrasound of both sides of head and neck blood flow | 100 | 100 |
| Injection, gadobutrol, 0.1 ml | 98 | 12 |
| Mri scan of blood vessels of head without contrast | 94 | 93 |
| Ct scan head or brain without contrast | 94 | 85 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Amitriptyline Hcl Other prescribers in Amherst, NY | 95 |
| Levetiracetam Other prescribers in Amherst, NY | 67 |
| Nurtec Odt (rimegepant sulfate) Other prescribers in Amherst, NY | 46 |
| Nortriptyline Hcl Other prescribers in Amherst, NY | 38 |
| Escitalopram Oxalate Other prescribers in Amherst, NY | 33 |
| Divalproex Sodium Er (divalproex sodium) Other prescribers in Amherst, NY | 30 |
| Gabapentin Other prescribers in Amherst, NY | 27 |
| Sumatriptan Succinate Other prescribers in Amherst, NY | 26 |
| Celecoxib Other prescribers in Amherst, NY | 24 |
| Dexamethasone Other prescribers in Amherst, NY | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 228 payments worth $52,454 in total to this clinician.
| Hyperfine Operations, Inc. | $27,030 |
|---|---|
| Lundbeck LLC | $12,154 |
| AbbVie Inc. | $10,637 |
| Pfizer Inc. | $608 |
| Teva Pharmaceuticals USA, Inc. | $392 |
| Tonix Medicines, Inc. | $371 |
| Currax Pharmaceuticals LLC | $198 |
| Averitas Pharma Inc. | $194 |
| Consulting Fee | $47,632 |
|---|---|
| Food and Beverage | $4,292 |
| Travel and Lodging | $439 |
| Education | $91.25 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Hyperfine Operations, Inc. Aug 6, 2025 | Consulting Fee Swoop · Portable MRI | $26,825 |
| Lundbeck LLC Apr 2, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $10,800 |
| AbbVie Inc. Jan 9, 2025 | Consulting Fee BOTOX · FACIAL AESTHETICS | $7,475 |
| AbbVie Inc. Jan 9, 2025 | Consulting Fee BOTOX · FACIAL AESTHETICS | $975 |
| AbbVie Inc. Dec 18, 2025 | Consulting Fee BOTOX · FACIAL AESTHETICS | $650 |
| AbbVie Inc. Jan 9, 2025 | Travel and Lodging BOTOX · FACIAL AESTHETICS · travel to CHICAGO, IL · in-kind | $439 |
| Lundbeck LLC Mar 12, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $424 |
| Teva Pharmaceuticals USA, Inc. Nov 18, 2025 | Education in-kind | $91.25 |
| Lundbeck LLC Jul 1, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $79.06 |
| Lundbeck LLC Apr 4, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $65.25 |
All 17 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Dec 18, 2025 | Consulting Fee BOTOX · FACIAL AESTHETICS | $650 |
| Teva Pharmaceuticals USA, Inc. Nov 18, 2025 | Education in-kind | $91.25 |
| Hyperfine Operations, Inc. Aug 6, 2025 | Consulting Fee Swoop · Portable MRI | $26,825 |
| Lundbeck LLC Jul 1, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $79.06 |
| Lundbeck LLC Apr 4, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $65.25 |
| Lundbeck LLC Apr 4, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $64.75 |
| Lundbeck LLC Apr 4, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $64.20 |
| Lundbeck LLC Apr 4, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $45.09 |
| Lundbeck LLC Apr 4, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $13.57 |
| Lundbeck LLC Apr 2, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $10,800 |
| Lundbeck LLC Mar 12, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $424 |
| Lundbeck LLC Mar 10, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $46.00 |
| Lundbeck LLC Mar 10, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $45.00 |
| Lundbeck LLC Feb 21, 2025 | Consulting Fee VYEPTI · NEUROLOGY | $60.00 |
| AbbVie Inc. Jan 9, 2025 | Consulting Fee BOTOX · FACIAL AESTHETICS | $7,475 |
| AbbVie Inc. Jan 9, 2025 | Consulting Fee BOTOX · FACIAL AESTHETICS | $975 |
| AbbVie Inc. Jan 9, 2025 | Travel and Lodging BOTOX · FACIAL AESTHETICS · travel to CHICAGO, IL · in-kind | $439 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 16 industry-funded studies in 2025, from 5 companies. The companies reported $1,299,699 in research payments for these studies, mostly to the institutions running them.
- A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
Eli Lilly and Company · Active, not recruiting · NCT06859268 - A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Completed · NCT06683508 - HYP-SWOOP-001
Hyperfine Operations, Inc. - A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Completed · NCT06230523 - M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. - Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy
Eli Lilly and Company · Status unknown · NCT02968303 - A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Recruiting · NCT06143956 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. · Active, not recruiting · NCT06417775 - A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT06603571 - A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine
Merz Pharmaceuticals, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.